Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery

References

• Aly SA, Boothe DM, Suh S. A novel alanine to serine substitution mutation in SoxS induces overexpression of efflux pumps and contributes to multidrug resistance in clinical Escherichia coli isolates. J Antimicrob Chemother. 2015;70(8):2228–2233.
   PubMed Web of Science ®Google Scholar
• Bergman AM, Pinedo HM, Talianidis I, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003;88(12):1963–1970.
   PubMed Web of Science ®Google Scholar
• Ghandadi M, Sahebkar A. Interleukin-6: a critical cytokine in cancer multidrug resistance. Curr Pharm Des. 2016;22(5):518–526.
   PubMed Web of Science ®Google Scholar
• Tang R, Faussat A-M, Majdak P, et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia. 2004;18(7):1246–1251.
   PubMed Web of Science ®Google Scholar
• Antonin D, Shai R, François-Xavier L, et al. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma. J Neurooncol. 2018;138(3):479–486.
   Web of Science ®Google Scholar
• Cheng GZ, Chan J, Wang Q, et al. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 2007;67(5):1979–1987.
   PubMed Web of Science ®Google Scholar
• Yao Q, Choi JH, Dai Z, et al. Improving tumor specificity and anticancer activity of dasatinib by dual-targeted polymeric micelles. ACS Appl Mater Interfaces. 2017;9(42):36642–36654.
   PubMed Web of Science ®Google Scholar
• Koziolová E, Chytil P, Etrych T, et al. Ability of polymer-bound P-glycoprotein inhibitor ritonavir to overcome multidrug resistance in various resistant neuroblastoma cell lines. Anticancer Drugs. 2017;28(10):1126–1130.
   PubMed Web of Science ®Google Scholar
• Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. In: Yu D., Hung MC, editors. Breast cancer chemosensitivity. Springer; 2007. p. 23–30.
   Google Scholar
• Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003;10(2):159–165.
   PubMedGoogle Scholar
• Palmeira A, Sousa E, H Vasconcelos M, et al. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. 2012;19(13):1946–2025.
   PubMed Web of Science ®Google Scholar
• Cario E. P-glycoprotein multidrug transporter in inflammatory bowel diseases: more questions than answers. World J Gastroenterol. 2017;23(9):1513–1520.
   PubMed Web of Science ®Google Scholar
• Sosnik A. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “Generally Recognized As Safe” (GRAS) nanopharmaceuticals: a review. Adv Drug Deliv Rev. 2013;65(13–14):1828–1851.
   PubMed Web of Science ®Google Scholar
• Yan L, Yang Y, Zhang W, et al. Advanced materials and nanotechnology for drug delivery. Adv Mater. 2014;26(31):5533–5540.
   PubMed Web of Science ®Google Scholar
• Kirtane A, Kalscheuer S, Panyam J. Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities. Adv Drug Deliv Rev. 2013;65(13–14):1731.
   PubMed Web of Science ®Google Scholar
• Saneja A, Dubey D, Alam N, et al. Co-formulation of P-glycoprotein substrate and inhibitor in nanocarriers: an emerging strategy for cancer chemotherapy. Curr Cancer Drug Targets. 2014;14(5):419–433.
   PubMed Web of Science ®Google Scholar
• Gong M-Q, Wu J-L, Chen B, et al. Self-assembled polymer/inorganic hybrid nanovesicles for multiple drug delivery to overcome drug resistance in cancer chemotherapy. Langmuir. 2015;31(18):5115–5122.
   PubMed Web of Science ®Google Scholar
• Vance ME, Kuiken T, Vejerano EP, et al. Nanotechnology in the real world: redeveloping the nanomaterial consumer products inventory. Beilstein J Nanotechnol. 2015;6:1769.
   PubMed Web of Science ®Google Scholar
• Chimene D, Alge DL, Gaharwar AK. Two-dimensional nanomaterials for biomedical applications: emerging trends and future prospects. Adv Mater. 2015;27(45):7261–7284.
   PubMed Web of Science ®Google Scholar
• Yang C, Wu T, Qi Y, et al. Recent advances in the application of vitamin E TPGS for drug delivery. Theranostics. 2018;8(2):464.
   PubMed Web of Science ®Google Scholar
• Muthu MS, Kutty RV, Luo Z, et al. Theranostic vitamin E TPGS micelles of transferrin conjugation for targeted co-delivery of docetaxel and ultra bright gold nanoclusters. Biomaterials. 2015;39:234–248.
   PubMed Web of Science ®Google Scholar
• Kutty RV, Chia SL, Setyawati MI, et al. In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancer. Biomaterials. 2015;63:58–69.
   PubMed Web of Science ®Google Scholar
• Sun D, Wei X, Xue X, et al. Enhanced oral absorption and therapeutic effect of acetylpuerarin based on D-α-tocopheryl polyethylene glycol 1000 succinate nanoemulsions. Int J Nanomedicine. 2014;9:3413.
   PubMed Web of Science ®Google Scholar
• Assanhou AG, Li W, Zhang L, et al. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment. Biomaterials. 2015;73:284–295.
   PubMed Web of Science ®Google Scholar
• Cheng W, Liang C, Xu L, et al. TPGS functionalized polydopamine modified mesoporous silica as drug nanocarriers for enhanced lung cancer chemotherapy against multidrug resistance. Small. 2017;13(29). Available from: https://doi.org/10.1002/smll.201700623
   Web of Science ®Google Scholar
• Wang J, Sun J, Chen Q, et al. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Biomaterials. 2012;33(28):6877–6888.
   PubMed Web of Science ®Google Scholar
• Russo A, Pellosi DS, Pagliara V, et al. Biotin-targeted Pluronic(®) P123/F127 mixed micelles delivering niclosamide: a repositioning strategy to treat drug-resistant lung cancer cells. Int J Pharm. 2016;511(1):127–139.
   PubMedGoogle Scholar
• Zhang Z, Tan S, Feng -S-S. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials. 2012;33(19):4889–4906.
   PubMed Web of Science ®Google Scholar
• Collnot E-M, Baldes C, Wempe MF, et al. Mechanism of inhibition of P-glycoprotein mediated efflux by Vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm. 2007;4(3):465–474.
   PubMed Web of Science ®Google Scholar
• Wempe MF, Wright C, Little JL, et al. Inhibiting efflux with novel non-ionic surfactants: rational design based on vitamin E TPGS. Int J Pharm. 2009;370(1):93–102.
   PubMedGoogle Scholar
• Shafiei-Irannejad V, Samadi N, Salehi R, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 succinate nanoparticles. Pharm Res. 2018;35(6):119.
   PubMed Web of Science ®Google Scholar
• Wu B, Liang Y, Tan Y, et al. Genistein-loaded nanoparticles of star-shaped diblock copolymer mannitol-core PLGA-TPGS for the treatment of liver cancer. Mater Sci Eng C. 2016;59:792–800.
   PubMed Web of Science ®Google Scholar
• Zeng X, Tao W, Wang Z, et al. Docetaxel loaded nanoparticles of dendritic amphiphilic block copolymer H40 PLA b TPGS for cancer treatment. Part Part Syst Characterization. 2015;32(1):112–122.
   Web of Science ®Google Scholar
• Tang X, Liang Y, Feng X, et al. Co-delivery of docetaxel and poloxamer 235 by PLGA-TPGS nanoparticles for breast cancer treatment. Mater Sci Eng C Mater Biol Appl. 2015;49:348–355.
   PubMed Web of Science ®Google Scholar
• Gaspar VM, Moreira AF, Costa EC, et al. Gas-generating TPGS-PLGA microspheres loaded with nanoparticles (NIMPS) for co-delivery of minicircle DNA and anti-tumoral drugs. Colloids Surf B Biointerfaces. 2015;134:287–294.
   PubMed Web of Science ®Google Scholar
• Wang J, Li L, Du Y, et al. Improved oral absorption of doxorubicin by amphiphilic copolymer of lysine-linked ditocopherol polyethylene glycol 2000 succinate: in vitro characterization and in vivo evaluation. Mol Pharm. 2015;12(2):463.
   PubMedGoogle Scholar
• Ai X, Sun J, Zhong L, et al. Star shape redox responsive PEG sheddable copolymer of disulfide linked polyethylene glycol lysine di tocopherol succinate for tumor triggering intracellular doxorubicin rapid release: head to head comparison. Macromol Biosci. 2015;14(10):1415–1428.
   Web of Science ®Google Scholar
• Cao N, Feng -S-S. Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials. 2008;29(28):3856–3865.
   PubMed Web of Science ®Google Scholar
• Bao Y, Guo Y, Zhuang X, et al. d-α-Tocopherol polyethylene glycol succinate-based redox-sensitive paclitaxel prodrug for overcoming multidrug resistance in cancer cells. Mol Pharm. 2014;11(9):3196–3209.
   PubMed Web of Science ®Google Scholar
• Kutty RV, Feng -S-S. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials. 2013;34(38):10160–10171.
   PubMed Web of Science ®Google Scholar
• Anbharasi V, Cao N, Feng SS. Doxorubicin conjugated to D-α-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J Biomed Mater Res. 2010;94A(3):730–743.
   Web of Science ®Google Scholar
• Mi Y, Zhao J, Feng -S-S. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. J Control Release. 2013;169(3):185–192.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Lemieux P, Vinogradov S, et al. Pluronic® block copolymers: novel functional molecules for gene therapy. Adv Drug Deliv Rev. 2002;54(2):223–233.
   PubMed Web of Science ®Google Scholar
• Akash MSH, Rehman K. Recent progress in biomedical applications of Pluronic (PF127): pharmaceutical perspectives. J Control Release. 2015;209:120–138.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release. 2002;82(2–3):189–212.
   PubMed Web of Science ®Google Scholar
• Caramella CM, Rossi S, Ferrari F, et al. Mucoadhesive and thermogelling systems for vaginal drug delivery. Adv Drug Deliv Rev. 2015;92:39–52.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev. 2002;54(5):759–779.
   PubMed Web of Science ®Google Scholar
• Kabanov AV, Batrakova EV, Miller DW. Pluronic® block copolymers as modulators of drug efflux transporter activity in the blood–brain barrier. Adv Drug Deliv Rev. 2003;55(1):151–164.
   PubMed Web of Science ®Google Scholar
• Hong W, Chen D, Zhang X, et al. Reversing multidrug resistance by intracellular delivery of Pluronic® P85 unimers. Biomaterials. 2013;34(37):9602–9614.
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release. 2008;130(2):98–106.
   PubMed Web of Science ®Google Scholar
• Alakhova DY, Rapoport NY, Batrakova EV, et al. Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers. J Control Release. 2010;142(1):89–100.
   PubMed Web of Science ®Google Scholar
• Baek J-S, Cho C-W. Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles. Int J Pharm. 2015;478(2):617–624.
   PubMedGoogle Scholar
• Song CK, Balakrishnan P, Shim C-K, et al. Enhanced in vitro cellular uptake of P-gp substrate by poloxamer-modified liposomes (PMLs) in MDR cancer cells. J Microencapsul. 2011;28(6):575–581.
   PubMed Web of Science ®Google Scholar
• Sun Y, Wang Q, Chen J, et al. Temperature-sensitive gold nanoparticle-coated pluronic-PLL nanoparticles for drug delivery and chemo-photothermal therapy. Theranostics. 2017;7(18):4424.
   PubMed Web of Science ®Google Scholar
• Kim JK, Won Y-W, Lim KS, et al. Low-molecular-weight methylcellulose-based thermo-reversible gel/pluronic micelle combination system for local and sustained docetaxel delivery. Pharm Res. 2012;29(2):525–534.
   PubMed Web of Science ®Google Scholar
• Grimaudo MA, Pescina S, Padula C, et al. Poloxamer 407/TPGS mixed micelles as promising carriers for cyclosporine ocular delivery. Mol Pharm. 2018;15(2):571–584.
   PubMed Web of Science ®Google Scholar
• Lin J, Zhao C, Liu C, et al. Redox-responsive F127-folate/F127-disulfide bond-d-α-tocopheryl polyethylene glycol 1000 succinate/P123 mixed micelles loaded with paclitaxel for the reversal of multidrug resistance in tumors. Int J Nanomedicine. 2018;13:805–830.
   PubMed Web of Science ®Google Scholar
• Fang X, Xu Y, Wang S, et al. Pluronic F68-linoleic acid nano-spheres mediated delivery of gambogic acid for cancer therapy. AAPS PharmSciTech. 2017;18(1):147–155.
   PubMed Web of Science ®Google Scholar
• Dong H, Tian L, Gao M, et al. Promising galactose-decorated biodegradable poloxamer 188-PLGA diblock copolymer nanoparticles of resibufogenin for enhancing liver cancer therapy. Drug Deliv. 2017;24(1):1302–1316.
   PubMed Web of Science ®Google Scholar
• Kim T-Y, Kim D-W, Chung J-Y, et al. Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-Free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies [10.1158/1078-0432.CCR-03-0655]. Clin Cancer Res. 2004;10(11):3708.
   PubMed Web of Science ®Google Scholar
• Park IH, Sohn JH, Kim SB, et al. An open-label, randomized, parallel, Phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional Cremophor EL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer. Cancer Res Treat. 2017;49(3):569–577.
   PubMed Web of Science ®Google Scholar
• Hu C-M, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab. 2009;10(8):836–841.
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee JY, Lim SH, et al. A prospective phase II study of cisplatin and cremophor EL-free paclitaxel (Genexol-PM) in patients with unresectable thymic epithelial tumors. J Thorac Oncol. 2015;10(12):1800–1806.
   PubMed Web of Science ®Google Scholar
• Kim JY, Do YR, Song HS, et al. Multicenter phase II clinical trial of Genexol-PM® with gemcitabine in advanced biliary tract cancer. Anticancer Res. 2017;37(3):1467.
   PubMed Web of Science ®Google Scholar
• Nehate C, Jain S, Saneja A, et al. Paclitaxel formulations: challenges and novel delivery options. Curr Drug Deliv. 2014;11(6):666–686.
   PubMed Web of Science ®Google Scholar
• Li W, Li X, Gao Y, et al. Inhibition mechanism of P-glycoprotein mediated efflux by mPEG-PLA and influence of PLA chain length on P-glycoprotein inhibition activity. Mol Pharm. 2014;11(1):71–80.
   PubMedGoogle Scholar
• Xiao L, Xiong X, Sun X, et al. Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials. 2011;32(22):5148–5157.
   PubMed Web of Science ®Google Scholar
• Fan Z, Chen C, Pang X, et al. Adding Vitamin E-TPGS to the formulation of Genexol-PM: specially mixed micelles improve drug-loading ability and cytotoxicity against multidrug-resistant tumors significantly. PLoS One. 2015;10(5):e0120129.
   PubMed Web of Science ®Google Scholar
• Nieto Montesinos R, Béduneau A, Pellequer Y, et al. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. J Control Release. 2012;161(1):50–61.
   PubMed Web of Science ®Google Scholar
• Yan Z, Yang Y, Wei X, et al. Tumor-penetrating peptide mediation: an effective strategy for improving the transport of liposomes in tumor tissue. Mol Pharm. 2014;11(1):218–225.
   PubMedGoogle Scholar
• Stuart MAC, Huck WT, Genzer J, et al. Emerging applications of stimuli-responsive polymer materials. Nat Mater. 2010;9(2):101.
   PubMed Web of Science ®Google Scholar
• Butt AM, Amin MCIM, Katas H. Synergistic effect of pH-responsive folate-functionalized poloxamer 407-TPGS-mixed micelles on targeted delivery of anticancer drugs. Int J Nanomedicine. 2015;10:1321.
   PubMed Web of Science ®Google Scholar
• Bao Y, Guo Y, Zhuang X, et al. D-伪-tocopherol polyethylene glycol succinate-based redox-sensitive paclitaxel prodrug for overcoming multidrug resistance in cancer cells. Mol Pharm. 2014;11(9):3196.
   PubMed Web of Science ®Google Scholar
• Bao Y, Kong M, Gao X, et al. pH-, redox dual-sensitive poly (β-amino ester)-g-TPGS copolymer nanoparticles for drug delivery and inhibition of multidrug resistance in cancer. Reactive and Functional Polymers. 2017;120:131–138.
   Web of Science ®Google Scholar
• Yao Q, Kou L, Tu Y, et al. MMP-Responsive ‘smart’ drug delivery and tumor targeting. Trends Pharmacol Sci. 2018;39(8):766–781.
   PubMed Web of Science ®Google Scholar
• Tu Y, Zhu L. Enhancing cancer targeting and anticancer activity by a stimulus-sensitive multifunctional polymer-drug conjugate. J Controlled Release. 2015;212:94–102.
   PubMed Web of Science ®Google Scholar
• Dai Z, Yao Q, Zhu L. MMP2-sensitive PEG-Lipid copolymers: a new type of tumor-targeted P-glycoprotein inhibitor. ACS Appl Mater Interfaces. 2016;8(20):12661–12673.
   PubMed Web of Science ®Google Scholar
• Dai Z, Tu Y, Zhu L. Multifunctional micellar nanocarriers for tumor-targeted delivery of hydrophobic drugs. J Biomed Nanotechnol. 2016;12(6):1199–1210.
   PubMed Web of Science ®Google Scholar
• Yao Q, Dai Z, Hoon Choi J, et al. Building stable MMP2-responsive multifunctional polymeric micelles by an all-in-one polymer–lipid conjugate for tumor-targeted intracellular drug delivery. ACS Appl Mater Interfaces. 2017;9(38):32520–32533.
   PubMed Web of Science ®Google Scholar
• Shono Y, Nishihara H, Matsuda Y, et al. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci. 2004;93(4):877–885.
   PubMed Web of Science ®Google Scholar
• Bakshi P, Sadhukhan S, Maiti S. Design of modified xanthan mini-matrices for monitoring oral discharge of highly soluble Soluplus®–glibenclamide dispersion. Mater Sci Engineering: C. 2015;54:169–175.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Minayian M, Yazdekhasti S. Physicochemical, pharmacodynamic and pharmacokinetic characterization of Soluplus stabilized nanosuspension of tacrolimus. Curr Drug Deliv. 2016;14(4):521.
   Web of Science ®Google Scholar
• Alvarez-Rivera F, Fernández-Villanueva D, Concheiro A, et al. α-lipoic acid in Soluplus(®) polymeric nanomicelles for ocular treatment of diabetes-associated corneal diseases. J Pharm Sci. 2016;105(9):2855–2863.
   PubMed Web of Science ®Google Scholar
• Shamma RN, Basha M. Soluplus®: a novel polymeric solubilizer for optimization of carvedilol solid dispersions: formulation design and effect of method of preparation. Powder Technology. 2013;237:406–414.
   Web of Science ®Google Scholar
• Linn M, Collnot E-M, Djuric D, et al. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. Eur J Pharm Sci. 2012;45(3):336–343.
   PubMed Web of Science ®Google Scholar
• Jin X, Zhou B, Xue L, et al. Soluplus® micelles as a potential drug delivery system for reversal of resistant tumor. Biomed Pharmacother. 2015;69:388–395.
   PubMed Web of Science ®Google Scholar
• Linn M In vitro characterization of the novel solubility enhancing excipient Soluplus®. 2011.
   Google Scholar
• Zhao J, Xu Y, Wang C, et al. Soluplus/TPGS mixed micelles for dioscin delivery in cancer therapy. Drug Dev Ind Pharm. 2017;43(7):1197–1204.
   PubMed Web of Science ®Google Scholar
• Bernabeu E, Gonzalez L, Cagel M, et al. Novel Soluplus®—TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines. Colloids Surf B Biointerfaces. 2016;140:403–411.
   PubMed Web of Science ®Google Scholar
• Liang R, Wei M, Evans DG, et al. Inorganic nanomaterials for bioimaging, targeted drug delivery and therapeutics. Chem Communications. 2014;50(91):14071–14081.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang R, Wu C, et al. The application of Fe3O4 nanoparticles in cancer research: a new strategy to inhibit drug resistance. J Biomed Mater Res. 2007;80A(4):852–860.
   Web of Science ®Google Scholar
• Jiang Z, Chen BA, Xia GH, et al. The reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells. Int J Nanomedicine. 2009;4(default):107–114.
   PubMedGoogle Scholar
• Chen B, Sun Q, Wang X, et al. Reversal in multidrug resistance by magnetic nanoparticle of Fe(3)O(4) loaded with adriamycin and tetrandrine in K562/A02 leukemic cells. Int J Nanomedicine. 2008;3(2):277–286.
   PubMed Web of Science ®Google Scholar
• Chen B-A, Mao P-P, Cheng J, et al. Reversal of multidrug resistance by magnetic Fe(3)O(4) nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells. Int J Nanomedicine. 2010;5:437–444.
   PubMed Web of Science ®Google Scholar
• Wu B, Torres-Duarte C, Cole BJ, et al. Copper oxide and zinc oxide nanomaterials act as inhibitors of multidrug resistance transport in sea urchin embryos: their role as chemosensitizers. Environ Sci Technol. 2015;49(9):5760–5770.
   PubMed Web of Science ®Google Scholar
• Yu J, Liu S, Wu B, et al. Comparison of cytotoxicity and inhibition of membrane ABC transporters induced by MWCNTs with different length and functional groups. Environ Sci Technol. 2016;50(7):3985–3994.
   PubMed Web of Science ®Google Scholar